Humira Biosimilar Coverage: Health New England Update
- health New England is set to switch its coverage of Humira, a biologic drug treating inflammatory conditions, to FDA-approved biosimilar medications for its commercial health plan members.
- Biosimilars mirror the efficacy and safety of thier biologic counterparts but at a reduced cost.
- The company is communicating directly with members, providers, and pharmacies to ensure a smooth transition to these cost-effective therapies.
Health New England is transitioning to Humira biosimilars starting July 1, aiming to reduce costs for members on its commercial health plans. This strategic shift to Humira biosimilars,including medications like Amjevita and Hadlima,mirrors a broader industry trend,promising more affordable healthcare without compromising quality. Gary Tereso,Health New England’s director of pharmacy Services,highlights this as a notable possibility to enhance affordability. The change ensures members receive the full benefits of their medications. Health New England is actively communicating with members, providers, and pharmacies to facilitate a smooth transition to these cost-effective therapies. Stay informed with News Directory 3. Discover what’s next for this Humira biosimilars and other biologic medications landscape.
Health New England transitions to Humira Biosimilars for Cost Savings
Updated June 11, 2025
health New England is set to switch its coverage of Humira, a biologic drug treating inflammatory conditions, to FDA-approved biosimilar medications for its commercial health plan members. This shift to biosimilars, like amjevita and Hadlima, seeks to make healthcare more affordable while maintaining quality of care.
Biosimilars mirror the efficacy and safety of thier biologic counterparts but at a reduced cost. Gary Tereso, director of Pharmacy services at Health New England, said this transition offers a ”meaningful possibility to enhance affordability” within the healthcare system. The change, effective July 1, aligns with industry trends to lower medication expenses.
The company is communicating directly with members, providers, and pharmacies to ensure a smooth transition to these cost-effective therapies. Health New England will also monitor the biosimilar market to support member needs and manage healthcare costs related to Humira biosimilars and other biologic medications.
“Biologic medications like Humira are complex treatments that carry meaningful cost. Its biosimilars provide a meaningful opportunity to enhance affordability for the healthcare ecosystem while members continue to get the full benefits of the medication,” said Gary Tereso,director of Pharmacy Services at Health New England.
What’s next
health New England will continue to monitor the biosimilar market and work with members to ensure a seamless transition to the new medications.